Proliferation markers of human pituitary tumors: Contribution of a genome-wide transcriptome approach

Molecular and Cellular Endocrinology

Volumn 326, Issue 1-2, 2010, Pages 30-39

  Wierinckx, Anne ^a,b   Raverot, Gérald ^a,c   Nazaret, Nicolas ^b   Jouanneau, Emmanuel ^a,c   Auger, Carole ^a   Lachuer, Joël ^a,b   Trouillas, Jacqueline ^a,c  

^a UNIVERSITÉ LYON 1   (France)

^b ProfileXpert   (France)

^c HOSPICES CIVILS DE LYON   (France)

Author keywords

Molecular markers; Pituitary tumors; Transcriptome

Indexed keywords

FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR BETA; FIBROBLAST GROWTH FACTOR BETA RECEPTOR; GONADOTROPIN; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45B; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR RECEPTOR; HIGH MOBILITY GROUP A PROTEIN; HIGH MOBILITY GROUP A2 PROTEIN; INHIBITOR OF DIFFERENTIATION 1; PROLACTIN; PROTEIN VIM; RNA; SOMATOMEDIN BINDING PROTEIN 5; SPERMIDINE SYNTHASE; TUMOR PROTEIN; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN; ZINC FINGER PROTEIN 36L1;

ACTH SECRETING ADENOMA; CANCER INVASION; CARCINOGENESIS; CELL CYCLE REGULATION; CELL PROLIFERATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GROWTH HORMONE SECRETING ADENOMA; HORMONE RELEASE; HUMAN; HYPOPHYSIS ADENOMA; HYPOPHYSIS TUMOR; MICROARRAY ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROLACTINOMA; REVIEW; RNA ANALYSIS; TRANSCRIPTOMICS; TUMOR CLASSIFICATION;

EID: 77955319259     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2010.02.043     Document Type: Review

References (56)

1. Agarwal R., Gonzalez-Angulo A.M., Myhre S., Carey M., Lee J.S., Overgaard J., Alsner J., Stemke-Hale K., Lluch A., Neve R.M., Kuo W.L., Sorlie T., Sahin A., Valero V., Keyomarsi K., Gray J.W., Borresen-Dale A.L., Mills G.B., Hennessy B.T. Integrative analysis of cyclin protein levels identifies cyclin b1 as a classifier and predictor of outcomes in breast cancer. Clin. Cancer Res. 2009, 15:3654-3662.
2. Andrews P.D., Knatko E., Moore W.J., Swedlow J.R. Mitotic mechanics: the auroras come into view. Curr. Opin. Cell Biol. 2003, 15:672-683.
3. Asa S.L., Ezzat S. The cytogenesis and pathogenesis of pituitary adenomas. Endocr. Rev. 1998, 19:798-827.
4. Baek S.H., Kioussi C., Briata P., Wang D., Nguyen H.D., Ohgi K.A., Glass C.K., Wynshaw-Boris A., Rose D.W., Rosenfeld M.G. Regulated subset of G1 growth-control genes in response to derepression by the Wnt pathway. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:3245-3250.
5. Casero R.A., Celano P., Ervin S.J., Applegren N.B., Wiest L., Pegg A.E. Isolation and characterization of a cDNA clone that codes for human spermidine/spermine N1-acetyltransferase. J. Biol. Chem. 1991, 266:810-814.
6. Criswell T.L., Arteaga C.L. Modulation of NFkappaB activity and E-cadherin by the type III transforming growth factor beta receptor regulates cell growth and motility. J. Biol. Chem. 2007, 282:32491-32500.
7. Crosby M.E., Almasan A. Opposing roles of E2Fs in cell proliferation and death. Cancer Biol. Ther. 2004, 3:1208-1211.
8. Daniel L., Trouillas J., Renaud W., Chevallier P., Gouvernet J., Rougon G., Figarella-Branger D. Polysialylated-neural cell adhesion molecule expression in rat pituitary transplantable tumors (spontaneous mammotropic transplantable tumor in Wistar-Furth rats) is related to growth rate and malignancy. Cancer Res. 2000, 60:80-85.
9. De Martino I., Visone R., Wierinckx A., Palmieri D., Ferraro A., Cappabianca P., Chiappetta G., Forzati F., Lombardi G., Colao A., Trouillas J., Fedele M., Fusco A. HMGA proteins up-regulate CCNB2 gene in mouse and human pituitary adenomas. Cancer Res. 2009, 69:1844-1850.
10. Evans C.O., Moreno C.S., Zhan X., McCabe M.T., Vertino P.M., Desiderio D.M., Oyesiku N.M. Molecular pathogenesis of human prolactinomas identified by gene expression profiling, RT-qPCR, and proteomic analyses. Pituitary 2008, 11:231-245.
11. Evans C.O., Young A.N., Brown M.R., Brat D.J., Parks J.S., Neish A.S., Oyesiku N.M. Novel patterns of gene expression in pituitary adenomas identified by complementary deoxyribonucleic acid microarrays and quantitative reverse transcription-polymerase chain reaction. J. Clin. Endocrinol. Metab. 2001, 86:3097-3107.
12. Ezzat S., Zheng L., Zhu X.F., Wu G.E., Asa S.L. Targeted expression of a human pituitary tumor-derived isoform of FGF receptor-4 recapitulates pituitary tumorigenesis. J. Clin. Investig. 2002, 109:69-78.
13. Farrell W.E. Pituitary tumours: findings from whole genome analyses. Endocr. Relat. Cancer 2006, 13:707-716.
14. Fedele M., Battista S., Kenyon L., Baldassarre G., Fidanza V., Klein-Szanto A.J., Parlow A.F., Visone R., Pierantoni G.M., Outwater E., Santoro M., Croce C.M., Fusco A. Overexpression of the HMGA2 gene in transgenic mice leads to the onset of pituitary adenomas. Oncogene 2002, 21:3190-3198.
15. Fedele M., Pentimalli F., Baldassarre G., Battista S., Klein-Szanto A.J., Kenyon L., Visone R., De Martino I., Ciarmiello A., Arra C., Viglietto G., Croce C.M., Fusco A. Transgenic mice overexpressing the wild-type form of the HMGA1 gene develop mixed growth hormone/prolactin cell pituitary adenomas and natural killer cell lymphomas. Oncogene 2005, 24:3427-3435.
16. Fedele M., Visone R., De Martino I., Troncone G., Palmieri D., Battista S., Ciarmiello A., Pallante P., Arra C., Melillo R.M., Helin K., Croce C.M., Fusco A. HMGA2 induces pituitary tumorigenesis by enhancing E2F1 activity. Cancer Cell 2006, 9:459-471.
17. Figarella-Branger D., Trouillas J. The new WHO classification of human pituitary tumors: comments. Acta Neuropathol. 2006, 111:71-72.
18. Graham D.K., Dawson T.L., Mullaney D.L., Snodgrass H.R., Earp H.S. Cloning and mRNA expression analysis of a novel human protooncogene, c-mer. Cell Growth Differ. 1994, 5:647-657.
19. Gurlek A., Karavitaki N., Ansorge O., Wass J.A. What are the markers of aggressiveness in prolactinomas? Changes in cell biology, extracellular matrix components, angiogenesis and genetics. Eur. J. Endocrinol. 2007, 156:143-153.
20. Horvath E., Kovacs K., Killinger D.W., Smyth H.S., Platts M.E., Singer W. Silent corticotropic adenomas of the human pituitary gland: a histologic, immunocytologic, and ultrastructural study. Am. J. Pathol. 1980, 98:617-638.
21. Hsu D.W., Hakim F., Biller B.M., de la Monte S., Zervas N.T., Klibanski A., Hedley-Whyte E.T. Significance of proliferating cell nuclear antigen index in predicting pituitary adenoma recurrence. J. Neurosurg. 1993, 78:753-761.
22. Jaffrain-Rea M.L., Di Stefano D., Minniti G., Esposito V., Bultrini A., Ferretti E., Santoro A., Faticanti Scucchi L., Gulino A., Cantore G. A critical reappraisal of MIB-1 labelling index significance in a large series of pituitary tumours: secreting versus non-secreting adenomas. Endocr. Relat. Cancer 2002, 9:103-113.
23. Kaltsas G.A., Nomikos P., Kontogeorgos G., Buchfelder M., Grossman A.B. Clinical review: diagnosis and management of pituitary carcinomas. J. Clin. Endocrinol. Metab. 2005, 90:3089-3099.
24. Kane M.A., Elwood P.C., Portillo R.M., Antony A.C., Kolhouse J.F. The interrelationship of the soluble and membrane-associated folate-binding proteins in human KB cells. J. Biol. Chem. 1986, 261:15625-15631.
25. Kane M.A., Portillo R.M., Elwood P.C., Antony A.C., Kolhouse J.F. The influence of extracellular folate concentration on methotrexate uptake by human KB cells. Partial characterization of a membrane-associated methotrexate binding protein. J. Biol. Chem. 1986, 261:44-49.
26. Kioussi C., Briata P., Baek S.H., Rose D.W., Hamblet N.S., Herman T., Ohgi K.A., Lin C., Gleiberman A., Wang J., Brault V., Ruiz-Lozano P., Nguyen H.D., Kemler R., Glass C.K., Wynshaw-Boris A., Rosenfeld M.G. Identification of a Wnt/Dvl/beta-Catenin→Pitx2 pathway mediating cell-type-specific proliferation during development. Cell 2002, 111:673-685.
27. Knosp E., Kitz K., Perneczky A. Proliferation activity in pituitary adenomas: measurement by monoclonal antibody Ki-67. Neurosurgery 1989, 25:927-930.
28. Kumagai H., Sato N., Yamada M., Mahony D., Seghezzi W., Lees E., Arai K., Masai H. A novel growth- and cell cycle-regulated protein, ASK, activates human Cdc7-related kinase and is essential for G1/S transition in mammalian cells. Mol. Cell. Biol. 1999, 19:5083-5095.
29. Levy A., Hall L., Yeudall W.A., Lightman S.L. p53 gene mutations in pituitary adenomas: rare events. Clin. Endocrinol. (Oxf.) 1994, 41:809-814.
30. Lloyd R.V., Kovacs K., Young W.F., Farrel W.E., Asa S.L., Trouillas J., Kontogeorgeos G., Sano T., Scheithauer B.W., Horvath E. Pituitary tumors: introduction. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Endocrine Organs 2004, 10-13. IARC Press, Lyon. R.A. DeLellis, R.V. Lloyd, P.U. Heitz, C. Eng (Eds.).
31. Lloyd R.V., Scheithauer B.W., Kuroki T., Vidal S., Kovacs K., Stefaneanu L. Vascular endothelial growth factor (VEGF) expression in human pituitary adenomas and carcinomas. Endocr. Pathol. 1999, 10:229-235.
32. Meij B.P., Lopes M.B., Ellegala D.B., Alden T.D., Laws E.R. The long-term significance of microscopic dural invasion in 354 patients with pituitary adenomas treated with transsphenoidal surgery. J. Neurosurg. 2002, 96:195-208.
33. Moreno C.S., Evans C.O., Zhan X., Okor M., Desiderio D.M., Oyesiku N.M. Novel molecular signaling and classification of human clinically nonfunctional pituitary adenomas identified by gene expression profiling and proteomic analyses. Cancer Res. 2005, 65:10214-10222.
34. Morris D.G., Musat M., Czirjak S., Hanzely Z., Lillington D.M., Korbonits M., Grossman A.B. Differential gene expression in pituitary adenomas by oligonucleotide array analysis. Eur. J. Endocrinol. 2005, 153:143-151.
35. Pegg A.E. Spermidine/spermine-N(1)-acetyltransferase: a key metabolic regulator. Am. J. Physiol. 2008, 294:E995-1010.
36. Pei L., Melmed S. Isolation and characterization of a pituitary tumor-transforming gene (PTTG). Mol. Endocrinol. Baltimore, Md 1997, 11:433-441.
37. Pei L., Melmed S., Scheithauer B., Kovacs K., Prager D. H-ras mutations in human pituitary carcinoma metastases. J. Clin. Endocrinol. Metab. 1994, 78:842-846.
38. Raverot G., Wierinckx A., Dantony E., Auger C., Chapas G., Villeneuve L., Brue T., Figarella-Branger D., Roy P., Jouanneau E., Jan M., Lachuer J., Trouillas J., and the members of HYPOPRONOS, 2010. Prognostic Factors in Prolactin Pituitary Tumors: Clinical, Histological, and Molecular Data from a Series of 94 Patients with a Long Postoperative Follow-Up. J. Clin. Endocrinol. Metab., 2010 Feb 17, doi:10.1210/jc.2009-1191.
39. Ray D., Melmed S. Pituitary cytokine and growth factor expression and action. Endocr. Rev. 1997, 18:206-228.
40. Scheithauer B.W., Kovacs K.T., Laws E.R., Randall R.V. Pathology of invasive pituitary tumors with special reference to functional classification. J. Neurosurg. 1986, 65:733-744.
41. Shi L., Reid L.H., Jones W.D., Shippy R., Warrington J.A., Baker S.C., Collins P.J., de Longueville F., Kawasaki E.S., Lee K.Y., Luo Y., Sun Y.A., Willey J.C., Setterquist R.A., Fischer G.M., Tong W., Dragan Y.P., Dix D.J., Frueh F.W., Goodsaid F.M., Herman D., Jensen R.V., Johnson C.D., Lobenhofer E.K., Puri R.K., Schrf U., Thierry-Mieg J., Wang C., Wilson M., Wolber P.K., Zhang L., Amur S., Bao W., Barbacioru C.C., Lucas A.B., Bertholet V., Boysen C., Bromley B., Brown D., Brunner A., Canales R., Cao X.M., Cebula T.A., Chen J.J., Cheng J., Chu T.M., Chudin E., Corson J., Corton J.C., Croner L.J., Davies C., Davison T.S., Delenstarr G., Deng X., Dorris D., Eklund A.C., Fan X.H., Fang H., Fulmer-Smentek S., Fuscoe J.C., Gallagher K., Ge W., Guo L., Guo X., Hager J., Haje P.K., Han J., Han T., Harbottle H.C., Harris S.C., Hatchwell E., Hauser C.A., Hester S., Hong H., Hurban P., Jackson S.A., Ji H., Knight C.R., Kuo W.P., LeClerc J.E., Levy S., Li Q.Z., Liu C., Liu Y., Lombardi M.J., Ma Y., Magnuson S.R., Maqsodi B., McDaniel T., Mei N., Myklebost O., Ning B., Novoradovskaya N., Orr M.S., Osborn T.W., Papallo A., Patterson T.A., Perkins R.G., Peters E.H., Peterson R., et al. The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat. Biotechnol. 2006, 24:1151-1161.
42. Sun L., Chen C. Expression of transforming growth factor beta type III receptor suppresses tumorigenicity of human breast cancer MDA-MB-231 cells. J. Biol. Chem. 1997, 272:25367-25372.
43. Tang B.L. ADAMTS: a novel family of extracellular matrix proteases. Int. J. Biochem. Cell. Biol. 2001, 33:33-44.
44. Tourniaire J., Trouillas J., Chalendar D., Bonneton-Emptoz A., Goutelle A., Girod C. Somatotropic adenoma manifested by galactorrhea without acromegaly. J. Clin. Endocrinol. Metab. 1985, 61:451-453.
45. Trouillas J., Daniel L., Guigard M.P., Tong S., Gouvernet J., Jouanneau E., Jan M., Perrin G., Fischer G., Tabarin A., Rougon G., Figarella-Branger D. Polysialylated neural cell adhesion molecules expressed in human pituitary tumors and related to extracellular invasion. J. Neurosurg. 2003, 98:1084-1093.
46. Trouillas J., Girod C. Pathology of pituitary adenoma. Pituitary Adenomas 1996, 22-46. Churchill Livingstone New York Publishers. A.M. Landolt, M.L. Vance, P.L. Reilly (Eds.).
47. Trouillas J., Girod C., Claustrat B., Joly-Pharaboz M.O., Chevallier P. Spontaneous prolactin transplantable tumor in the Wistar/Furth rat (SMtTW): a new animal model of human prolactinoma. Cancer Res. 1990, 50:4081-4086.
48. Turley R.S., Finger E.C., Hempel N., How T., Fields T.A., Blobe G.C. The type III transforming growth factor-beta receptor as a novel tumor suppressor gene in prostate cancer. Cancer Res. 2007, 67:1090-1098.
49. Vigneron S., Prieto S., Bernis C., Labbe J.C., Castro A., Lorca T. Kinetochore localization of spindle checkpoint proteins: who controls whom?. Mol. Biol. Cell 2004, 15:4584-4596.
50. Wang L., Darling J., Zhang J.S., Liu W., Qian J., Bostwick D., Hartmann L., Jenkins R., Bardenhauer W., Schutte J., Opalka B., Smith D.I. Loss of expression of the DRR 1 gene at chromosomal segment 3p21.1 in renal cell carcinoma. Genes Chromosomes Cancer 2000, 27:1-10.
51. Whitfield M.L., George L.K., Grant G.D., Perou C.M. Common markers of proliferation. Nat. Rev. 2006, 6:99-106.
52. Wierinckx A., Auger C., Devauchelle P., Reynaud A., Chevallier P., Jan M., Perrin G., Fevre-Montange M., Rey C., Figarella-Branger D., Raverot G., Belin M.F., Lachuer J., Trouillas J. A diagnostic marker set for invasion, proliferation, and aggressiveness of prolactin pituitary tumors. Endocr. Relat. Cancer 2007, 14:887-900.
53. Yao X., Abrieu A., Zheng Y., Sullivan K.F., Cleveland D.W. CENP-E forms a link between attachment of spindle microtubules to kinetochores and the mitotic checkpoint. Nat. Cell Biol. 2000, 2:484-491.
54. Yu R., Lu W., Chen J., McCabe C.J., Melmed S. Overexpressed pituitary tumor-transforming gene causes aneuploidy in live human cells. Endocrinology 2003, 144:4991-4998.
55. Zhang X., Horwitz G.A., Heaney A.P., Nakashima M., Prezant T.R., Bronstein M.D., Melmed S. Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. J. Clin. Endocrinol. Metab. 1999, 84:761-767.
56. Zou Z., Anisowicz A., Hendrix M.J., Thor A., Neveu M., Sheng S., Rafidi K., Seftor E., Sager R. Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science New York, NY 1994, 263:526-529.